Gilteritinib
Small molecule
Evidence outlook
Approved: Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 1/2 · investigational in the US
Also approved (4)
- Conditional approval for relapsed or refractory AML with a FLT3 mutation
- Xospata® (gilteritinib tablets) is indicated for: the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation. A validated test is required to confirm the FLT3 mutation status of AML.
- Monotherapy for adults with relapsed or refractory AML with a FLT3 mutation
- FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (XOSPATA 40 mg tablets); first approval worldwide
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02997202 NCT02997202 · Acute Myeloid Leukemia This was a randomized, quadruple-blind, placebo-controlled trial with 178 participants per group and a hard clinical primary endpoint of relapse-free survival. The primary endpoint was not statistically significant (hazard ratio 0.679; p=0.0518), so the results provide well-controlled but inconclusive evidence of benefit. Registry: NCT02997202 | 3 | Relapse-free Survival (RFS) (From the date of randomization up to 64 months and 22 days) 2023-01-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
View 2 more trials
NCT02752035 NCT02752035 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation The study randomized participants to active treatment groups, including gilteritinib plus azacitidine versus azacitidine alone, but it was not blinded and the gilteritinib-only arm was removed from randomization during the study. Overall survival, the hard clinical primary endpoint, was not significantly improved with the combination (p=0.523), supporting a moderate evidence grade rather than a strong one. Registry: NCT02752035 | 3 | Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)) 2023-03-10 | Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) | Partial signal | link ↗ |
NCT02421939 NCT02421939 · Relapsed/Refractory Acute Myeloid Leukemia Registry: NCT02421939 | 3 | Duration of Overall Survival (OS) (From randomization to until the date of death from any cause (median time of follow-up for OS was 17.8 months)); Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm (From the date of randomization up to at least 112 days) 2018-09-17 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Competitive landscape
Other FLT3 drugs
Quizartinib, Clifutinib Besylate, XY0206, anti-CI135 CAR-T. Compare all 5 FLT3 drugs
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Gilteritinib: this drug | Approved | Small molecule | FLT3 | Partial signal | NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed | |
| Azacitidine (Onureg) | Approved | Small molecule | DNMT1 (DNA methyltransferase 1) | Weak signal | NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results). | |
| Decitabine / Cedazuridine (Inqovi) | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | Partial signal | Featured results are non-efficacy only in this race | |
| Enasidenib (Idhifa) | Approved | Small molecule | IDH2 | Partial signal | NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed | |
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | Partial signal | NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients. | |
| Glasdegib | Approved | Small molecule | Hedgehog Pathway Inhibitor | Partial signal | No reviewed efficacy summary in this indication | |
| Ivosidenib (Tibsovo) | Approved | Small molecule | Mutant IDH1 | Reliable signal | NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis) | |
| Midostaurin (Rydapt) | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | Weak signal | NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results). | |
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | Weak signal | Featured results are safety only in this race | |
| Orca-T (TREGZI) | Approved | Cell therapy | Allogeneic engineered T-cell immunotherapy | Partial signal | NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5) | |
| Quizartinib | Approved | Small molecule | FLT3 | Reliable signal | NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Sargramostim (Leukine) | Approved | Protein / enzyme therapeutic | GM-CSF receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tretinoin (Vesanoid) | ApprovedUS marketing discontinued | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL | not yet graded | NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending | |
| Venetoclax | Approved | Small molecule | BCL-2 | Reliable signal | NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed | |
| Vyxeos | Approved | Small molecule | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II | Partial signal | NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1). | |
| Ziftomenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| 131I-Apamistamab | Phase 3 | Monoclonal antibody | CD45 | Partial signal | NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001 | |
| Arsenic Trioxide (QTX-2101) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | not yet graded | No reviewed efficacy summary in this indication | |
| Arsenic Trioxide (SDK001) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | Partial signal | No reviewed efficacy summary in this indication | |
| Azacitidine | Phase 3 | Small molecule | DNMT1 (DNA methyltransferase 1) | Partial signal | NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed | |
| Bleximenib | Phase 3 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Clifutinib Besylate | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Crenolanib | Phase 3 | Small molecule | FLT3 (including D835/ITD mutants), also PDGFR-alpha/beta | Reliable signal | NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145) | |
| Galinpepimut-S | Phase 3 | Vaccine | WT1 (Wilms Tumor-1 protein) | Weak signal | NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47% | |
| Lisaftoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mocravimod | Phase 3 | Small molecule | Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruserontinib | Phase 3 | Small molecule | FLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes) | Partial signal | No reviewed efficacy summary in this indication | |
| XY0206 | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Annamycin | Phase 2/3 | Small molecule | Topoisomerase II (TOP2) | not yet graded | No reviewed efficacy summary in this indication | |
| BL-M11D1 | Phase 2/3 | Antibody–drug conjugate | CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| Pivekimab Sunirine (Decnupaz) | Phase 2/3 | Antibody–drug conjugate | CD123 | not yet graded | No reviewed efficacy summary in this indication | |
| Cusatuzumab | Phase 2 | Monoclonal antibody | CD70 | Weak signal | NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38 | |
| Lintuzumab-Ac225 | Phase 2 | Radiopharmaceutical | CD33 | Weak signal | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 2 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | Weak signal | NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months | |
| Prexigebersen | Phase 2 | RNA / oligonucleotide | GRB2 (growth factor receptor-bound protein 2) mRNA | Weak signal | Featured results are safety only in this race | |
| Romaciclib | Phase 2 | Small molecule | CDK8 / CDK19 | Weak signal | NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response | |
| Sonrotoclax (Beqalzi) | Phase 2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tagraxofusp | Phase 2 | Protein / enzyme therapeutic | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| Vididencel | Phase 2 | Vaccine | Allogeneic dendritic cell vaccine | Weak signal | NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported). | |
| AB8939 | Phase 1/2 | Small molecule | Tubulin | not yet graded | No reviewed efficacy summary in this indication | |
| ABD-3001 | Phase 1/2 | Small molecule | ALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1) | not yet graded | No reviewed efficacy summary in this indication | |
| Alrizomadlin | Phase 1/2 | Small molecule | MDM2 | Weak signal | No reviewed efficacy summary in this indication | |
| ARD103 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD3632 | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Bexmarilimab | Phase 1/2 | Monoclonal antibody | Clever-1 | not yet graded | No reviewed efficacy summary in this indication | |
| BG1805 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| BSB-1001 | Phase 1/2 | Cell therapy | HA-1 (minor histocompatibility antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| CART84 | Phase 1/2 | Cell therapy | CD84 | not yet graded | No reviewed efficacy summary in this indication | |
| CCTx-001 | Phase 1/2 | Cell therapy | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| CD123 Targeted CAR-NK Cells | Phase 1/2 | Cell therapy | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| CD123 / CD33 CART | Phase 1/2 | Cell therapy | CD123 / CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-049 | Phase 1/2 | Multispecific antibody | FLT3, CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Debio 1562M | Phase 1/2 | Antibody–drug conjugate | CD37 | not yet graded | No reviewed efficacy summary in this indication | |
| Emavusertib | Phase 1/2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enzomenib | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Ligufalimab | Phase 1/2 | Monoclonal antibody | CD47 | not yet graded | No reviewed efficacy summary in this indication | |
| Mobinitinib | Phase 1/2 | Small molecule | FLT3 / Aurora kinase A and B | not yet graded | No reviewed efficacy summary in this indication | |
| MRX-2843 | Phase 1/2 | Small molecule | Flt3/MerTK | Weak signal | No reviewed efficacy summary in this indication | |
| Ocifisertib | Phase 1/2 | Small molecule | PLK4 (Polo-like kinase 4) | Weak signal | Featured results are safety only in this race | |
| Olverembatinib | Phase 1/2 | Small molecule | BCR-ABL (also AKT, c-Kit, ERK) | not yet graded | No reviewed efficacy summary in this indication | |
| OrcaGraft (Orca-Q) | Phase 1/2 | Cell therapy | Treg-enriched allogeneic haematopoietic stem cell graft | not yet graded | No reviewed efficacy summary in this indication | |
| Rogocekib | Phase 1/2 | Small molecule | CLK (CDC-like kinase family) | not yet graded | No reviewed efficacy summary in this indication | |
| Anti-CI135 CAR-T | Phase 1 | Cell therapy | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| PRGN-3006 | Phase 1 | Cell therapy | CD33 | Weak signal | NCT03927261: PRGN-3006 (NCT03927261): no dose-limiting toxicities (DLTs) observed. | |
| BMF-500 | Discontinued | — | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Camibirstat | Discontinued | Small molecule | SMARCA4/SMARCA2 (BRG1/BRM ATPase subunits) | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 67 furthest-along competitors are listed; 63 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Gilteritinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (8)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (2)
June 2027 (2)
October 2027 (1)
What to watch
2028 (12)
January 2028 (2)
May 2028 (2)
July 2028 (2)
August 2028 (2)
September 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (8)
February 2029 (1)
What to watch
April 2029 (1)
What to watch
May 2029 (2)
June 2029 (1)
What to watch
October 2029 (1)
What to watch
2030 (1)
May 2030 (1)
What to watch
2032 (1)
December 2032 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent